OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
John H. Strickler, Hironaga Satake, Thomas J. George, et al.
New England Journal of Medicine (2022) Vol. 388, Iss. 1, pp. 33-43
Open Access | Times Cited: 256
John H. Strickler, Hironaga Satake, Thomas J. George, et al.
New England Journal of Medicine (2022) Vol. 388, Iss. 1, pp. 33-43
Open Access | Times Cited: 256
Showing 1-25 of 256 citing articles:
Pancreatic cancer: Advances and challenges
Christopher J. Halbrook, Costas A. Lyssiotis, Marina Pasca di Magliano, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1729-1754
Open Access | Times Cited: 529
Christopher J. Halbrook, Costas A. Lyssiotis, Marina Pasca di Magliano, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1729-1754
Open Access | Times Cited: 529
Neoadjuvant therapy for pancreatic cancer
Christoph Springfeld, Cristina R. Ferrone, Matthew H. G. Katz, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 5, pp. 318-337
Closed Access | Times Cited: 205
Christoph Springfeld, Cristina R. Ferrone, Matthew H. G. Katz, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 5, pp. 318-337
Closed Access | Times Cited: 205
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Marwan Fakih, Lisa Salvatore, Taito Esaki, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 23, pp. 2125-2139
Closed Access | Times Cited: 157
Marwan Fakih, Lisa Salvatore, Taito Esaki, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 23, pp. 2125-2139
Closed Access | Times Cited: 157
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Adrian G. Sacher, Patricia LoRusso, Manish R. Patel, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 8, pp. 710-721
Open Access | Times Cited: 151
Adrian G. Sacher, Patricia LoRusso, Manish R. Patel, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 8, pp. 710-721
Open Access | Times Cited: 151
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
Tanios Bekaii‐Saab, Rona Yaeger, Alexander I. Spira, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 25, pp. 4097-4106
Open Access | Times Cited: 140
Tanios Bekaii‐Saab, Rona Yaeger, Alexander I. Spira, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 25, pp. 4097-4106
Open Access | Times Cited: 140
Therapeutic developments in pancreatic cancer
Zilun Hu, Eileen M. O’Reilly
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 7-24
Closed Access | Times Cited: 123
Zilun Hu, Eileen M. O’Reilly
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 7-24
Closed Access | Times Cited: 123
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M.F. Mosele, C. Benedikt Westphalen, A Stenzinger, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 588-606
Open Access | Times Cited: 80
M.F. Mosele, C. Benedikt Westphalen, A Stenzinger, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 588-606
Open Access | Times Cited: 80
Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 927-936
Open Access | Times Cited: 55
Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 927-936
Open Access | Times Cited: 55
New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 48
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 48
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 38
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 38
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Xinyuan Tong, Ayushi Patel, Eejung Kim, et al.
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 413-428.e7
Open Access | Times Cited: 33
Xinyuan Tong, Ayushi Patel, Eejung Kim, et al.
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 413-428.e7
Open Access | Times Cited: 33
Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 24
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 24
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
Ryan B. Corcoran, Khanh Do, Jeong Eun Kim, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 9, pp. 1739-1749
Open Access | Times Cited: 15
Ryan B. Corcoran, Khanh Do, Jeong Eun Kim, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 9, pp. 1739-1749
Open Access | Times Cited: 15
KRAS G12C inhibitor combination therapies: current evidence and challenge
Hirotaka Miyashita, Shumei Kato, David S. Hong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
Hirotaka Miyashita, Shumei Kato, David S. Hong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma
Carter Norton, Matthew Shaw, Zachary Rubnitz, et al.
JAMA Network Open (2025) Vol. 8, Iss. 1, pp. e2453588-e2453588
Open Access | Times Cited: 2
Carter Norton, Matthew Shaw, Zachary Rubnitz, et al.
JAMA Network Open (2025) Vol. 8, Iss. 1, pp. e2453588-e2453588
Open Access | Times Cited: 2
Advances in the management of pancreatic cancer
Marco Del Chiaro, Toshitaka Sugawara, Sana D. Karam, et al.
BMJ (2023), pp. e073995-e073995
Open Access | Times Cited: 36
Marco Del Chiaro, Toshitaka Sugawara, Sana D. Karam, et al.
BMJ (2023), pp. e073995-e073995
Open Access | Times Cited: 36
State-of-the-Art and Upcoming Innovations in Pancreatic Cancer Care: A Step Forward to Precision Medicine
Tommaso Schepis, Sara Sofia De Lucia, Antonio Pellegrino, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3423-3423
Open Access | Times Cited: 35
Tommaso Schepis, Sara Sofia De Lucia, Antonio Pellegrino, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3423-3423
Open Access | Times Cited: 35
The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer
Vishnu Kumarasamy, Jianxin Wang, Costakis Frangou, et al.
Cancer Research (2024) Vol. 84, Iss. 7, pp. 1115-1132
Open Access | Times Cited: 14
Vishnu Kumarasamy, Jianxin Wang, Costakis Frangou, et al.
Cancer Research (2024) Vol. 84, Iss. 7, pp. 1115-1132
Open Access | Times Cited: 14
HSP70-mediated mitochondrial dynamics and autophagy represent a novel vulnerability in pancreatic cancer
Giulia D. S. Ferretti, Colleen E. Quaas, Irene Bertolini, et al.
Cell Death and Differentiation (2024) Vol. 31, Iss. 7, pp. 881-896
Open Access | Times Cited: 14
Giulia D. S. Ferretti, Colleen E. Quaas, Irene Bertolini, et al.
Cell Death and Differentiation (2024) Vol. 31, Iss. 7, pp. 881-896
Open Access | Times Cited: 14
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Anna Linehan, Mary O’Reilly, Ray McDermott, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 13
Anna Linehan, Mary O’Reilly, Ray McDermott, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 13
Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors
Marcell Baranyi, Eszter Molnár, Luca Hegedűs, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 6, pp. 1059-1072
Open Access | Times Cited: 12
Marcell Baranyi, Eszter Molnár, Luca Hegedűs, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 6, pp. 1059-1072
Open Access | Times Cited: 12
Next-generation therapies for pancreatic cancer
Conor Buckley, Eileen M. O’Reilly
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 1-3, pp. 55-72
Open Access | Times Cited: 12
Conor Buckley, Eileen M. O’Reilly
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 1-3, pp. 55-72
Open Access | Times Cited: 12
